|
|
Obesity Treatment Market Research
 | |  |
| |
Global Information, Inc. offers market intelligence on every topic in the Obesity Treatment Market, including, but not limited to latest trend on: Anti-Obesity; Weight Control; Obesity Treatment; Anti-dyslipidemic Therapeutic; Slimming Meals; Diet Food.
We offer market research, industry forecasts, and business analysis in the Obesity Treatment Market as well as other vertical industries. GII sells reports, databases, newsletters and annual information services that provide the latest market data, such as industry forecasts, projections, trends, market shares, research and development, sales and marketing strategies, and competitive analysis. The easiest way to find out if we have the information you need is to contact us right now. We are open 24 hours a day, 5 days a week with multiple language support. Please see our Contact page to see which office is open right now.
|
|
 | |  |
Reports
| European Markets for Obesity Surgery Devices |
|
| Published : 2008/04 |
| This research service examines the European obesity surgery devices markets in terms of the challenges faced by market participants, drivers and restraints in the industry, the competitive structure in the major markets, the revenue forecasts,growth rates ... |
| European Gastroenterology Therapeutics Markets |
|
| Published : 2007/11 |
| This Frost & Sullivan research service titled European Gastroenterology Therapeutics Markets provides an overview of current treatment options, technological advancements and revenues, along with a complete analysis of key prevailing drivers, restraints a ... |
| Anti-Obesity Treatments 2007-2012 - A blockbuster target market |
|
| Published : 2007/07 |
| Anti-Obesity Treatments 2007-2012, examines the market for anti-obesity drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a d ... |
| The U.S. Weight Loss & Diet Control Market (9th Edition) |
|
| Published : 2007/04 |
| This is a completely revised and updated analysis of Marketdata' s best- selling biennial study about the $55 billion U.S. weight loss market. This is the most comprehensive investigation of the U.S. weight loss market published by anyone worldwide, cover ... |
| Clinical Management of Obesity |
|
| Published : 2006/06 |
| This Frost & Sullivan research service titled Clinical Management of Obesity provides an in-depth analysis about the various commercial weight-loss products and therapies currently available in the market, and those on the verge of commercialization. ... |
| Weight Control Products & Services |
|
| Published : 2004/02 |
| Demand for weight control products and services in the US will advance 6.9 percent annually to over $21 billion in 2008. Weight control products are projected to generate demand of $12 billion in 2008, which will represent an average annual gain of 6.3 pe ... |
| Weight Loss Markets: Products, Services, Foods and Beverages |
|
| Published : 2003/12 |
| The report analyzes the current and anticipated future size of the total weight loss/control market. In addition to the two-way division, discussed above, it also provides similar data for the five-product/service segments into which we have divided the t ... |
| Pipeline Insight: Dyslipidemia - Shift from statins to add-ons |
|
| Published : 2003/08 |
| In the absence of pipeline compounds that can exceed the efficacy of statins, a number of trends have been identified. Pipeline developments are focusing on therapies that target lipid parameters inadequately controlled with statins, adjunctive therapies ... |
| Weight Control - US - June 2003 |
|
| Published : 2003/06 |
| The consumer intelligence series of reports published from 2001 displays Mintel's commitment to the US market, providing market intelligence based on original and unique data, as well as years of experience. ... |
| Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor? |
|
| Published : 2003/05 |
| Statins are undisputedly the gold standard in the treatment of dyslipidemia and more efficacious monotherapies are unlikely to be identified and developed in the near future. However, an important unmet need lies in the effective control of patients with ... |
|
|
View Cart
